Literature DB >> 6093522

Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen.

R W Bradsher, R M Snow.   

Abstract

A randomized trial to compare the efficacy and safety of 1 g of ceftriaxone daily and 3 to 4 g of cefazolin daily was conducted in 84 hospitalized adults with skin and soft tissue infections. A variety of infections including bacteriologically proven cellulitis, suppurative diabetic foot ulcer, soft tissue abscess, and other miscellaneous infections were treated. Side effects were minimal. Colonization with various microorganisms was observed during therapy with both agents. Clinical cure with or without surgery was achieved in 81 percent (34) of 42 patients treated with ceftriaxone and 77 percent (32) of 42 patients treated with cefazolin. The major difference between antibiotics was the rate of failure in infections caused by multiple organisms: five failures among 13 patients treated with cefazolin compared with no failures among 12 patients treated with ceftriaxone. Ceftriaxone appears to be an effective agent when given once daily as therapy for many serious skin and soft tissue infections.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093522

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

Review 1.  Diagnostics and treatment of the diabetic foot.

Authors:  Jan Apelqvist
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

2.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

3.  Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections.

Authors:  S Segev; R Raz; E Rubinstein; H Shmuely; D Hassin; N Rosen; E Platau; S Ben Assuli; S Pitlik
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-10       Impact factor: 3.267

Review 4.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

5.  Randomized, double-blind trial of cefonicid and nafcillin in the treatment of skin and skin structure infections.

Authors:  J S Daly; M G Worthington; R J Andrews; R B Brown; R Schwartz; D J Sexton
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

Review 7.  Interventions for cellulitis and erysipelas.

Authors:  Sally A Kilburn; Peter Featherstone; Bernie Higgins; Richard Brindle
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.